Adherence to bisphosphonate therapy in postmenopausal osteoporotic women.
Kuzmanova, Stefka Iv; Solakov, Panayot C; Geneva-Popova, Mariela G.
Folia Med (Plovdiv)
; 53(3): 25-31, 2011.
Artigo em Inglês | MEDLINE | ID: mdl-22359979
Effectiveness of monthly intravenous ibandronate on the low responders to oral bisphosphonate: the MOVEMENT study.
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Comparative adherence to weekly oral and quarterly intravenous bisphosphonates among patients with limited heath literacy who sustained distal radius fractures.
The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis.
Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO).
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
The role of i.v. ibandronate administration in osteoporosis therapy.
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis.